

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date: March 1, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations








Table 1: Population Characteristics of COVID-19 Breakthrough Cases

	Overal	
All	<i>N</i> 131096 1	% .nn
Age (in years)	131090	00
0-4	11	0
5-11	1583	1
12-17	6015	5
18-24	11162	9
25-49	57051	
50-64		24
65+	23995	18
Gender	23993	10
Male Male	57159	44
Female	72977	56
Unknown	960	1
Race/Ethnicity	900	'
	27139	21
Hispanic White	42038	32
Black	10375	
		13
API	16868	
AEA	457	0
Other	9241	7
Unknown	24978	19
Travel History	==00	
Yes	5788	4
No	36897	28
Unknown	88411	67
Hospitalization		
Yes	3450	3
No	41670	32
Unknown	85976	66
Death		
Yes	1219	1
No	10327	8
Unknown	119550	91
Vaccine Type		
Pfizer	87618	67
Novavax	6	0
Unknown	1127	1
Moderna	35266	27
Janssen	7078	5
Emergen	1	0
Underlying Conditions		
Yes	20444	16
No	110651	84
Unknown	1	0

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
883685	131096	1434489	469080	14835	32700



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations

	Over	Overall	
	Ν	%	
All	3450	100	
Age (in years)			
5-11	5	0	
12-17	20	1	
18-24	36	1	
25-49	351	10	
50-64	599	17	
65+	2439	71	
Gender			
Male	1869	54	
Female	1577	46	
Unknown	4	0	
Race/Ethnicity			
Hispanic	429	12	
White	2008	58	
Black	386	11	
API	341	10	
AEA	16	0	
Other	107	3	
Unknown	163	5	
Travel History			
Yes	146	4	
No	1773	51	
Unknown	1531	44	
Death			
Yes	862	25	
No	629	18	
Unknown	1959	57	
Vaccine Type			
Pfizer	2005	58	
Unknown	88	3	
Moderna	1106	32	
Janssen	251	7	
Underlying Conditions			
Yes	2488	72	
No	962	28	



Table 4:Population Characteristics of COVID-19 Breakthrough Deaths

	Over	Overall	
	Ν	%	
All	1219	100	
Age (in years)			
25-49	35	3	
50-64	148	12	
65+	1036	85	
Gender			
Male	736	60	
Female	483	40	
Race/Ethnicity			
Hispanic	133	11	
White	824	68	
Black	126	10	
API	115	9	
AEA	6	0	
Other	10	1	
Unknown	5	0	
Hospitalization			
Yes	862	71	
No	77	6	
Unknown	280	23	
Vaccine Type			
Pfizer	670	55	
Unknown	30	2	
Moderna	398	33	
Janssen	121	10	
Underlying Conditions			
Yes	696	57	
No	523	43	

Table 5: Breakthrough Death Rates

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
883685	1219	1434489	8090	138	564

^{*} Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson salanssen vaccine.



Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	2488	72
	No	962	28
Hypertension	Yes	1582	N/A
Immunocompromised	Yes	138	N/A
Chronic Heart Disease	Yes	742	N/A
Chronic Liver Disease	Yes	63	N/A
Chronic Kidney Disease	Yes	488	N/A
Diabetes	Yes	921	N/A
Neurologic/Neurodevelopmental	Yes	208	N/A
Chronic Lung Disease	Yes	655	N/A
Historically Healthy	Yes	301	N/A

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	696	57
	No	523	43
Hypertension	Yes	448	N/A
Immunocompromised	Yes	49	N/A
Chronic Heart Disease	Yes	252	N/A
Chronic Liver Disease	Yes	25	N/A
Chronic Kidney Disease	Yes	190	N/A
Diabetes	Yes	269	N/A
Neurologic/Neurodevelopmental	Yes	61	N/A
Chronic Lung Disease	Yes	198	N/A
Historically Healthy	Yes	26	N/A

Notes:

^{*} White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

^{*} The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

^{*} The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).